This article provides a snapshot of the synthetic biology market in a number of key industries and explores how disruptive technologies can significantly alter the way businesses operate across any market space.
Join Nerac President and CEO, Kevin Bouley, as he answers questions about the company. In this video, Kevin discusses how Nerac has brought value to one of our clients, and how we can do the same for you.
While clinical data is required for manufacturers of high risk devices and implants, the vast majority of manufacturers that make low-to-medium risk devices may not need to conduct clinical trials for their products or produce peer-reviewed literature that supports their clinical use. This article helps identify the specific clauses of the guidance document that pertain to clinical data and explores alternative pathways to compliance.